Dyspnea Treatment Market: Introduction
- Dyspnea can be defined as shortness of breath, also known as air hunger. The shortness of breath can range between mild to temporary and serious and long lasting. Dyspnea can be caused due to spending time on high altitudes, overexertion, or as a symptom of a range of other conditions.
- Signs of dyspnea include shortness of breath due to exertion or due to a medical condition; labored breathing, rapid shallow breathing, heart palpitations, wheezing, coughing, tightness in the chest, and suffocation as a result of breathing difficulties
- The common causes of dyspnea include heart failure, chronic obstructive pulmonary disease (COPD), pneumonia, asthma, and interstitial lung disease, and psychogenic problems related to anxiety
Key Drivers and Restraints of Global Dyspnea Treatment Market
- The global dyspnea treatment market is driven by rise in prevalence of dyspnea among the population owing to surge in prevalence of its causative symptoms such as COPD and asthma. The prevalence of dyspnea is considered to be high, with over 25% patients affected globally.
- High prevalence of cardiopulmonary diseases, rise in obesity among people, and lifestyle changes are the major causes of dyspnea. Increase in presence of target population necessitates the demand for dyspnea treatment. This in turn contributes to the growth of the global market.
- Exposure to various toxins and increasing levels of air pollution leading to breathlessness among the population boosts the growth of the global dyspnea treatment market
- However, lack of awareness among people and limited operating revenue opportunities for players focused on developing targeted therapies for dyspnea treatment are likely to hamper the growth of the global dyspnea treatment market during the forecast period.
North America to Lead Global Dyspnea Treatment Market
- In terms of region, the global dyspnea treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America dominated the global dyspnea treatment market in 2019, owing to strong presence of leading market players, increase in product approvals, well-established health care infrastructure, and high prevalence of obesity and cardiopulmonary diseases
- Europe was the second largest market for dyspnea treatment in 2019. Asia Pacific is projected to be the fastest growing market for dyspnea treatment, followed by Latin America and Middle East & Africa. Growing focus of governments of countries in Asia on enhancing health care facilities, increase in focus of players on leveraging opportunities offered by emerging economies, and rise in prevalence of asthma and COPD among people are expected to augment the dyspnea treatment market in the region.
Key Players Operating in Global Dyspnea Treatment Market
Leading players in the global dyspnea treatment market are:
- Mayne Pharma Group Limited
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Bausch Health
- Hikma Pharmaceuticals plc
- Lannett Company, Inc.
- Amneal Pharmaceuticals LLC
- Mylan N.V.
- Lupin Limited
- Akron Incorporated
- ANI Pharmaceuticals, Inc.
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
Global Dyspnea Treatment Market: Research Scope
Global Dyspnea Treatment Market, by Treatment
- Therapy
- Supplemental Oxygen Therapy
- Relaxation Therapy
- Drugs
- Antianxiety Drugs
- Antibiotics
- Anticholinergic Agents
- Corticosteroids
- Others
Global Dyspnea Treatment Market, by Route of Administration
Global Dyspnea Treatment Market, by End-user
- Hospitals
- Home Care
- Specialty Centers
- Others
Global Dyspnea Treatment Market, by Region
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
